NASDAQ · Biotechnology

KROS (KROS) Stock

$10.42 +2.06% NASDAQ: KROS Healthcare

Valuation

MetricValue
Price$10.42
Market Cap$333.42M
P/E Ratio4.60
P/B Ratio1.12
P/S Ratio10.59
EPS (TTM)$2.30
52-Week High$22.55
52-Week Low$9.69
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE28.71%
ROA25.74%
ROCE23.43%
Gross Margin29.10%
Operating Margin29.10%
Net Margin-2.57%
Debt/Equity0.06
Current Ratio15.75

Annual Financials (USD)

Metric20212022202320242025
Revenue$20.0M$0$0$4.0M$244.0M
Operating Profit$-56.0M$-115.0M$-170.0M$-211.0M$71.0M
Net Profit$-59.0M$-105.0M$-153.0M$-187.0M$87.0M
EPS$-2.52$-4.15$-5.20$-5.00$2.30
Op Margin-280.5%—-112543.7%-5939.0%28.9%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$255.0M$307.0M$370.0M$616.0M$338.0M
Total Liabilities$12.0M$29.0M$38.0M$44.0M$35.0M
Cash$230.0M$279.0M$331.0M$560.0M$287.0M
Borrowings$1.0M$13.0M$14.0M$19.0M$17.0M

Latest News

Nurix Therapeutics (NRIX) Soars 16.4%: Is Further Upside Left in the Stock? Zacks · Jun 26, 2026 Keros Therapeutics Appoints Anne Prener to its Board of Directors GlobeNewswire · Jun 25, 2026 Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference GlobeNewswire · Jun 1, 2026 KROS Turns to Next Wave of TGF-Beta Muscle Therapies Zacks · May 22, 2026 Should You Buy KROS After Q1 Miss and Takeda Deal Reset? Zacks · May 22, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-62.0M$-70.0M$-125.0M$-161.0M$108.0M
Investing Cash Flow$-2.0M$-2.0M$-5.0M$-4.0M$-3.0M
Financing Cash Flow$0$1.0M$3.0M$12.0M$-375.0M
Net Cash Flow$-35.0M$49.0M$52.0M$229.0M$-273.0M
Free Cash Flow$-63.0M$-71.0M$-127.0M$-163.0M$106.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA0.94
FCF Yield-16.58%
Quick Ratio22.62
Interest Coverage—
Return 1Y-29.73%
Return 3Y-76.42%
Return 5Y-73.29%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ABSI $7.13 -5.69% -11.32 $1.21B 0.00%
CRVS $13.31 +3.02% -23.00 $1.12B 0.00%
CTMX $3.37 +4.01% -24.27 $541.98M 0.00%
MLTX $19.57 -1.58% -4.71 $1.62B 0.00%
NAGE $3.12 +2.63% 18.75 $248.49M 0.00%

About KROS

KROS is led by CEO Jasbir S. Seehra, employs 163 people, headquartered in US, publicly traded since 2020.

KROS stock trades at $10.42 with a market capitalization of $333.42M. The stock is valued at a price-to-earnings (P/E) ratio of 4.60, price-to-book of 1.12, price-to-sales of 10.59. Over the past 52 weeks the stock has ranged between $9.69 and $22.55, and currently trades 53.8% below its 52-week high.

On profitability, KROS generates a return on equity (ROE) of 28.71% — well above the market average, a sign of a high-quality business, return on capital employed of 23.43%, an operating margin of 29.10%, a net profit margin of -2.57%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides